Cite
HARVARD Citation
Smith, M. et al. (n.d.). Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatric blood & cancer. 62 (1), pp. 91-98. [Online].